Original cohort | NACRT (n=6000) | PCh (n=3745) | ACRT (n=7953) | ACh (n=3000) | Surgery alone (n=15 184) | Total (n=21 384) |
Matched cohort | NACRT (n=2853) | PCh (n=1907) | ACRT (n=4188) | ACh (n=1744) | Surgery alone (n=10 692) | |
Age at diagnosis | ||||||
Median | 67.0 | 68.0 | 70.0 | 72.0 | 69.0 | 69.0 |
Range | (20.0 to 88.0) | (24.0 to 90.0) | (19.0 to 90.0) | (23.0 to 90.0) | (18.0 to 90.0) | (18.0 to 90.0) |
Sex | ||||||
Female | 539 (18.9%) | 667 (35%) | 1600 (38.2%) | 705 (40.4%) | 3511 (32.8%) | 7022 (32.8%) |
Race/ethnicity | ||||||
White | 2607 (91.4%) | 1264 (66.3%) | 2504 (59.8%) | 1126 (64.6%) | 7080 (66.2%) | 14 581 (68.2%) |
African American | 92 (3.2%) | 258 (13.5%) | 739 (17.6%) | 273 (15.7%) | 1476 (13.8%) | 2838 (13.3%) |
Asian | 51 (1.7%) | 115 (6.1%) | 449 (10.8%) | 155 (8.9%) | 743 (7.9%) | 1613 (7.5%) |
Hispanic | 76 (2.7%) | 234 (12.3%) | 439 (10.5%) | 171 (9.8%) | 1030 (9.6%) | 1950 (9.1%) |
Other and unknown | 27 (1%) | 36 (1.9%) | 57 (1.3%) | 19 (1.1%) | 263 (2.5%) | 402 (1.9%) |
Primary tumour location | ||||||
Cardia | 2706 (94.8%) | 815 (42.7%) | 1066 (25.5%) | 447 (25.6%) | 4253 (39.8%) | 9287 (43.4%) |
Non-cardia | 147 (5.2%) | 1092 (57.3%) | 3122 (74.5%) | 1297 (74.4%) | 6439 (60.2%) | 12 097 (56.6%) |
Histology | ||||||
Adenocarcinoma | 2248 (78.8%) | 1080 (56.6%) | 2124 (50.7%) | 869 (49.8%) | 6156 (57.6%) | 12 477 (58.3%) |
Diffuse | 282 (9.9%) | 415 (21.8%) | 1113 (26.6%) | 442 (25.3%) | 2071 (19.4%) | 4323 (20.2%) |
Intestinal | 87 (3%) | 192 (10.1%) | 523 (12.5%) | 206 (11.8%) | 1186 (11.1%) | 2194 (10.3%) |
Mucinous | 106 (3.7%) | 63 (3.3%) | 148 (3.5%) | 55 (3.2%) | 301 (2.8%) | 673 (3.1%) |
Others | 130 (4.6%) | 157 (8.2%) | 280 (6.7%) | 172 (9.9%) | 978 (9.1%) | 1717 (8%) |
Grade | ||||||
Poor or undifferentiated | 1387 (48.6%) | 1188 (62.3%) | 2895 (69.1%) | 1217 (69.8%) | 5946 (55.6%) | 12 633 (59.1%) |
Moderately differentiated | 946 (33.2%) | 512 (26.8%) | 1020 (24.4%) | 418 (24%) | 3185 (29.8%) | 6081 (28.4%) |
Well-differentiated | 126 (4.4%) | 49 (2.6%) | 126 (3%) | 51 (2.9%) | 713 (6.7%) | 1065 (5%) |
Unknown | 394 (13.8%) | 158 (8.3%) | 147 (3.5%) | 58 (3.3%) | 848 (7.9%) | 1605 (7.5%) |
TNM CLIN T stage | ||||||
0 | 2 (0.1%) | 11 (0.6%) | 5 (0.1%) | 2 (0.1%) | 29 (0.3%) | 49 (0.2%) |
1 | 161 (5.6%) | 140 (7.3%) | 357 (8.5%) | 169 (9.7%) | 2097 (19.6%) | 2924 (13.7%) |
2 | 488 (17.1%) | 323 (16.9%) | 523 (12.5%) | 223 (12.8%) | 1515 (14.2%) | 3072 (14.4%) |
3 | 1705 (59.8%) | 863 (45.3%) | 605 (14.4%) | 281 (16.1%) | 1142 (10.7%) | 4596 (21.5%) |
4 | 80 (2.8%) | 122 (6.4%) | 166 (4%) | 84 (4.8%) | 354 (3.3%) | 806 (3.8%) |
Unknown | 417 (14.6%) | 448 (23.5%) | 2532 (60.5%) | 985 (56.5%) | 5555 (52%) | 9937 (46.5%) |
TNM Clinical N Stage | ||||||
0 | 1027 (36%) | 722 (37.9%) | 1358 (32.4%) | 617 (35.4%) | 4858 (45.4%) | 8582 (40.1%) |
1 | 1283 (45%) | 710 (37.2%) | 518 (12.4%) | 250 (14.3%) | 924 (8.6%) | 3685 (17.2%) |
2 | 222 (7.8%) | 129 (6.8%) | 210 (5%) | 91 (5.2%) | 244 (2.3%) | 896 (4.2%) |
3 | 28 (1%) | 35 (1.8%) | 91 (2.2%) | 39 (2.2%) | 158 (1.5%) | 351 (1.6%) |
Unknown | 293 (10.3%) | 311 (16.3%) | 2011 (48%) | 747 (42.8%) | 4508 (42.2%) | 7870 (36.8%) |
Academic centre | ||||||
Yes | 1469 (51.5%) | 1048 (55%) | 1455 (34.7%) | 674 (38.6%) | 4665 (43.6%) | 9311 (43.5%) |
Insurance status | ||||||
Not Insured | 51 (1.8%) | 54 (2.8%) | 110 (2.6%) | 36 (2.1%) | 319 (3%) | 570 (2.7%) |
Private insurance | 1121 (39.3%) | 660 (34.6%) | 1282 (30.6%) | 486 (27.9%) | 3102 (29%) | 6651 (31.1%) |
Medicaid | 105 (3.7%) | 122 (6.4%) | 263 (6.3%) | 95 (5.4%) | 647 (6.1%) | 1232 (5.8%) |
Medicare | 1503 (52.7%) | 1022 (53.6%) | 2421 (57.8%) | 1082 (62%) | 6285 (58.8%) | 12 313 (57.6%) |
Other and unknown | 73 (2.5%) | 49 (2.6%) | 112 (2.7%) | 45 (2.6%) | 339 (3.2%) | 618 (2.9%) |
Charlson-Deyo Score | ||||||
0 | 1950 (68.3%) | 1286 (67.4%) | 2792 (66.7%) | 1091 (62.6%) | 7119 (66.6%) | 14 238 (66.6%) |
1 | 690 (24.2%) | 479 (25.1%) | 1014 (24.2%) | 471 (27%) | 2654 (24.8%) | 5308 (24.8%) |
2 | 213 (7.5%) | 142 (7.4%) | 382 (9.1%) | 182 (10.4%) | 919 (8.6%) | 1838 (8.6%) |
The numbers on the original cohort indicates the patients who met the inclusion criteria for this analysis, NACRT (6000), PCh (3745), ACRT (7953), ACh (3000), and surgery alone (15 184). The numbers for matched cohort is after matching by age, gender, and comorbidity index NACRT (2853), PCh (1907), ACRT (4188), ACh (1744), and surgery alone (10 692). The patients in the matched cohort are used to compare the outcomes between different treatments.
ACh, adjuvant chemotherapy; ACRT, adjuvant chemoradiation; ; NACRT, neoadjuvant chemoradiation; PCh, perioperative chemotherapy.